Development and regulation of cell-mediated immunity in experimental Leishmaniasis

Immunologic Research

Volumn 27, Issue 2-3, 2003, Pages 489-498

  Scott, Phillip ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cell mediated immunity; IL 12; Leishmania; Memory; Th cell subsets

Indexed keywords

INTERLEUKIN 12; LEISHMANIA VACCINE;

CELL ACTIVITY; CELL INTERACTION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFECTION RESISTANCE; LABORATORY; LEISHMANIA; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS; MEMORY CELL; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTOZOAL INFECTION; REINFECTION; REVIEW; TH1 CELL;

ANIMALS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; INTERLEUKIN-12; LEISHMANIASIS; TH1 CELLS;

EID: 0042520921     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:27:2-3:489     Document Type: Review

References (50)

1. Afonso LCC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P: The adjuvant effect of interleukin- 12 in a vaccine against Leishmania major. Science 1994; 263:235-237.
2. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P: Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001;69:245-251.
3. Park AY, Hondowicz BD, Scott P: IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 2000;165: 896-902.
4. Turk JL, Bryceson ADM: Immunologic phenomena in leprosy and related diseases. Adv Immunol 1971;13:209-266.
5. Scott P: Th cell development and regulation in experimental cutaneous leishmaniasis. Chem Immunol 1996;63:98-114.
6. Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
7. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A: Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988;168:1675-1684.
8. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM: Reciprocal expression of interferon gamma or IL4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989;169:59-72.
9. Noben-Trauth N, Kropf P, Muller I: Susceptibility to Leishmania major infection in interleukin-4 deficient mice. Science 1996;271: 987-990.
10. Kane MM, Mosser DM: The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001;166:1141-1147.
11. Chatelain R, Mauze S, Coffman RL: Experimental Leishmania major infection in mice: role of IL-10. Parasite Immunol 1999;21: 211-218.
12. Soong L, Duboise SM, Kima P, McMahon-Pratt D: Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995;63: 3559-3566.
13. Moll H, Fuchs H, Blank C, Rollinghoff M: Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. Eur J Immunol 1993;23:1595-1601.
14. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC: Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 1998;188: 1547-1552.
15. Konecny P, Stagg AJ, Jebbari H, English N, Davidson RN, Knight SC: Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12 p40 and stimulate primary T cell proliferation in vitro. Eur J Immunol 1999;29:1803-1811.
16. Marovich MA, McDowell MA, Thomas EK, Nutman TB: IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process. J Immunol 2000;164:5858-5865.
17. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR: CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-290.
18. Scharton TM, Scott P: Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-577.
19. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J, Hissong BD, et al.: T-bet is rapidly induced by interferon-gamma in lymphoid and myeloid cells. Proc Natl Acad Sci USA 2001;98: 15,137-15,142.
20. Jones D, Elloso MM, Showe L, Williams D, Trinchieri G, Scott P: Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect Immun 1998; 66:3818-3824.
21. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK: Recombinant Interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177: 1505-1509.
22. Sypek JP, Chung CL, Mayor SEH, Subramanyam JM, Goldman SJ, Sieburth DS, et al.: Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective Th1 immune response. J Exp Med 1993;177:1797-1802.
23. Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al.: WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001;15:569-578.
24. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL: The role of interleukin (IL)- 10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL- 10 receptor antibody for sterile cure. J Exp Med 2001; 194:1497-1506.
25. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, et al.: Expression cloning of a protective Leishmania antigen. Science 1995;268:563-566.
26. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC: Immunostimulatory oligodeoxy-nucleotides promote protective immunity and provide systemic therapy forleishmaniasis via IL- 12-and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999;96:6970-6975.
27. Stacey KJ, Blackwell JM: Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999;67: 3719-3726.
28. Gurunathan S, Prussin C, Sacks DL, Seder RA: Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998;4:1409-1415.
29. Gurunathan S, Stobie L, Prussin C, Sacks DL, Glaichenhaus N, Fowell DJ, et al.: Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: A potential immunoregulatory role for CD8+T cells. J Immuno1 2000; 165:915-924.
30. Hu H, Huston G, Duso D, Lepak N, Roman E, Swain SL: CD4(+) T cell effectors can become memory cells with high efficiency and without further division. Nat Immunol 2001;2:705-710.
31. Bell EB, Sparshott SM, Bunce C: CD4+ T-cell memory, CD45R subsets and the persistence of antigen - a unifying concept. Immunol Today 1998;19:60-64.
32. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-712.
33. Fearon DT, Manders P, Wagner SD: Arrested differentiation, the self-renewing memory lymphocyte, and vaccination. Science 2001;293:248-250.
34. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589-600.
35. Mocci S, Coffman RL: Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4. J Immunol 1995;154: 3779-3787.
36. Doyle AM, Mullen AC, Villarino AV, Hutchins AS, High FA, Lee HW, et al.: Induction of cytotoxic t lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J Exp Med 2001; 194:893-902.
37. Wang X, Mosmann T: In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J Exp Med 2001;194: 1069-1080.
38. Kim CH, Campbell DJ, Butcher EC: Nonpolarized memory T cells. Trends Immunol 2001;22:527-530.
39. Campbell DJ, Kim CH, Butcher EC: Separable effector T cell populations specialized for B cell help or tissue inflammation. Nat Immunol 2001;2:876-881.
40. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK: Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410:101-105.
41. Ahmadzadeh M, Hussain SF, Farber DL: Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells. J Immunol 2001;166: 926-935.
42. Gudmundsdottir H, Turka LA: A closer look at homeostatic proliferation of CD4(+) T cells: costimulatory requirements and role in memory formation. J Immunol 2001;167:3699-3707.
43. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, et al.: Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001;292:1907-1910.
44. Hondowicz BD, Park AY, Elloso MM, Scott P: Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice. Eur J Immunol 2000;30:2007-2014.
45. Park AY, Hondowicz B, Kopf M, Scott P: The role of IL- 12 in maintaining resistance to Leishmania major. J Immunol 2002;168: 5771-5777.
46. Reiner SL, Fowell DJ, Moskowitz NH, Swier K, Brown DR, Brown CR, et al.: Control of Leishmania major by a monoclonal αβ T cell repertoire. J Immunol 1998;160: 884-889.
47. Jones DE, Buxbaum LU, Scott P: IL-4-independent inhibition of IL- 12 responsiveness during Leishmania amazonensis infection. J Immunol 2000;165: 364-372.
48. Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, et al.: In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001;19: 23-45.
49. Hsieh C-S, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM: Development of Th1 CD4+ T cells through IL- 12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
50. Scott P: IL- 12: Initiation cytokine for cell-mediated immunity. Science 1993;260:496-497.